Researchers at the Institute of Robotics and Industrial Informatics -a joint center of the CSIC and the Polytechnic University of Catalonia-, and at the Sant Joan de Déu Hospital in Barcelona, have developed a system for helping in the diagnoses of rare diseases related to deficiencies in the structure of collagen VI.

The Instituto de la Grasa of the CSIC and the University of Sevilla have developed a method for analysing oral tolerance to lipids (triglycerides) from the diet, in humans, in only 4 hours. The method is easier and faster than the current ones.

RIS3 communities are groups between research institutions and companies, created at the request of the European Union to define and promote scientific projects in strategic sectors in the different European regions. In Catalonia, TEC-SALUT is one of these RIS3CAT communities. It encompasses several projects and has the participation of different CSIC centers. The goal is to create a collaborative space that responds to the challenges of the health system and health technologies.

Scientists at the Instituto de Óptica have developed a new intraocular lens, which changes shape to focus on distant and near objects in order to imitate the crystalline lens function. It is the result of the Presbyopia project, funded by the European Research Council (ERC).

A work demonstrates that peptides derived from a LRP1 receptor sequence are very effective inhibiting the aggregation of LDL (low density lipoprotein, also called 'bad' cholesterol) that takes place in the vascular wall during development of atherosclerosis. Only the introduction is translated

Scientists at the CSIC have developed new portable and non-invasive sensors for monitoring biomarkers such as glucose, lactate or alcohol. They are based on wireless electro chromic and electrochemical sensors, and they can be used to detect metabolites in biological fluids, either human fluids (sweat, urine…) or in fluids derived from food products (e.g., leaking).

CSIC and UAM have developed compounds that positively modulate protein-protein interactions that involve KChIP2protein. Industrial partners from the pharmaceutical industry are being sought to collaborate through a patent licence agreement.

MIN-102, a metabolite from a drug against diabetes, could be useful for treating some neurodegenerative diseases, as scientists think. To confirm this hypothesis, a project has been launched with the involvement of the CSIC’s Instituto de Investigaciones Biomédicas de Barcelona, the Hospital Universitari 'Sant Joan de Déu' and the University of Lleida. The research project is led by the company Mynorix Therapeutics.